Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP-G28 in Lactose Intolerance
NCT03597516Phase 3Completed
- Sponsor
- Ritter Pharmaceuticals
- Start
- Jun 2018
- Primary completion
- Jul 2019
- Modality
- Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of galacto-oligosaccharides in lactose intolerance, sponsored by Ritter Pharmaceuticals. Started Jun 2018; status: completed.
02
Drugs
galacto-oligosaccharides
03
Conditions
lactose intolerance
Beyond the preview
Go deeper on NCT03597516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03597516.